Skip to main content
. 2006 Jan 23;147(6):661–670. doi: 10.1038/sj.bjp.0706658

Figure 1.

Figure 1

The oral treatment with TR14035 (3 mg kg−1, 1 h before and 3 h after antigen challenge), an α4β1/α4β7 dual antagonist, produced a significant decrease of the airways hyper-responsiveness to 5-hydroxytryptamine (5-HT) in an experimental model of allergic asthma in Brown Norway rats. The airway responses to intravenous 5-HT are expressed as increases in lung resistance (RL) (a) and decreases in lung compliance (Cdyn) (b) obtained 24 h after challenge with antigen or saline. The experimental groups are: saline challenge without drug treatment (i.e. negative control; NS), antigen challenge without drug treatment (i.e. positive control; SZ), saline challenge in TR14035-treated rats (NS+TR14035), and antigen challenge in TR14035-treated rats (SZ+TR14035). Points are mean±s.e.m. of seven animals in each group except studies at 48 h which were carried out in five animals. *P<0.05 NS vs SZ, #P<0.05 SZ vs SZ+TR14035.